ASP Isotopes Inc. Provides Business Update

§ 01 Executive Snapshot

• What: ASP Isotopes Inc. provided a business update highlighting operational progress and future targets.
• Who: ASP Isotopes Inc., Paul Mann (Executive Chairman and CEO).
• Why it matters: The company is poised for significant growth in isotope production, with strategic expansions in nuclear medicine and energy sectors, targeting substantial EBITDA by 2031.

§ 02 Key Developments

• First commercial shipments of multiple isotopes, including Silicon-28, Carbon-14, and Ytterbium-176, are expected in 2026.
• The company has a target EBITDA of greater than $300 million by 2031.
• Cash, cash equivalents, and short-term marketable securities totaled $333 million as of December 31, 2025.

§ 03 Strategic Context

• The company is focused on developing technologies for critical materials used in nuclear medicine and energy, positioning itself at the forefront of isotope enrichment.
• ASP Isotopes is expanding operations internationally, including acquisitions in the U.S. radiopharmacy market, reflecting a strategic shift to capture new revenue streams.

§ 04 Strategic Implications

• Immediate implications include enhanced production capabilities and revenue growth from new isotope shipments, particularly in the medical and electronics sectors.
• Long-term, the focus on increasing EBITDA and operational expansion suggests a robust growth trajectory, potentially transforming ASP Isotopes into a leader in isotope production.

§ 05 Risks & Constraints

• Potential risks include regulatory challenges associated with nuclear material production and market competition in the isotope sector.
• Operational risks may arise from technical challenges in scaling production and maintaining supply chain stability for feedstock.

§ 06 Watchlist / Forward Signals

• Key upcoming milestones include the expected commercial shipments of enriched isotopes in 2026 and the business update conference call on April 13, 2026.
• Future developments to monitor include customer engagement outcomes for isotope offtake agreements and progress on the Helium Phase 1 capacity in Q3 2026.